Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF 1535 NEXT DPI versus pMDI and beclometasone DPI in adult asthma
2010-023281-47Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of beclometasone dipropionate + formoterol, beclomethasone dipropionate and formoterol in asthma (3 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Change from baseline to the entire treatment period in average pre-dose morning peak expiratory flow. Started Dec 2010; status: completed.
02
Drugs
beclometasone dipropionate + formoterolbeclomethasone dipropionateformoterol
03
Conditions
asthma
Beyond the preview
Go deeper on 2010-023281-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023281-47.